StreetInsider.com News Articles

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Wed, 25 Sep 2024 08:00:00 -0500

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings
Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the Company’s Rostock International Parkinson's Disease (ROPAD), further supporting the association of a RAB32 gene

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Wed, 25 Sep 2024 08:00:00 -0500

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings
Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Wed, 25 Sep 2024 08:00:00 -0500

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings
Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Wed, 25 Sep 2024 08:00:00 -0500

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings
Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Wed, 25 Sep 2024 08:00:00 -0500

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings
Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Wed, 25 Sep 2024 08:00:00 -0500

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings
Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population

Form 6-K Centogene N.V. For: Aug 19

Tue, 20 Aug 2024 06:01:00 -0500

si-local-file:///var/storage/secattach/20240820/23620479.html

Form 6-K Centogene N.V. For: Aug 19

Tue, 20 Aug 2024 06:01:00 -0500

si-local-file:///var/storage/secattach/20240820/23620479.html

Form 6-K Centogene N.V. For: Aug 07

Thu, 08 Aug 2024 06:02:00 -0500

si-local-file:///var/storage/secattach/20240808/23568845.html

Form 6-K Centogene N.V. For: Aug 07

Thu, 08 Aug 2024 06:02:00 -0500

si-local-file:///var/storage/secattach/20240808/23568845.html

CENTOGENE Receives Delisting Notice From Nasdaq

Wed, 07 Aug 2024 18:19:00 -0500

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq. The notice indicates that CENTOGENE (the “Company”) remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares.